Dose Optimization of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis of 50 mg Versus 100 mg Once Daily.

What was studied

This review asked if a lower dasatinib dose keeps efficacy and is safer. Dose-related toxicity may limit long-term tolerability at 100 mg. It compared 50 mg with 100 mg once daily. Patients were adults with chronic-phase chronic myeloid leukemia. Searches ran from inception to March 15, 2026. Of 613 records, 7 reports were kept. Few studies compared the doses directly. Single-arm 50 mg cohorts gave support. Risk ratios were pooled in random-effects models.

What they found

Major molecular response at 12 months was similar for both doses. The 50 mg dose did better on cytogenetic response, before any adjustment. The 50 mg dose cut pleural effusion. It also cut low platelet counts. Single-arm 50 mg data showed high pooled response at 12 months. The pooled rates were for 12-month MMR and CCyR.

What it means for patients

The authors say initial dasatinib 50 mg once daily may keep key efficacy. They say it may also improve tolerability.

Why it is not certain yet

Prospective controlled studies are needed. Few studies compared the doses directly. The cytogenetic result was unadjusted. Single-arm data are only supportive evidence.

Source

Dose Optimization of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis of 50 mg Versus 100 mg Once Daily.

We restate facts from the source record in our own words. The original wording belongs to its publisher.